Fresenius Medical Care named Korangy CEO. FMC stock gains 1.40 percent

Published on 10/13/2026 at 09:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 1.40 percent to EUR 4.86 billion in the second quarter. FMC stock costs EUR 38.43 on October 13, 2026 versus EUR 37.90.

Key points in brief

Fresenius Medical Care appointed Shervin J. Korangy CEO effective October 12, 2026.
Second-quarter 2026 revenue rose 1.40 percent year over year to EUR 4.86 billion.
FMC stock was at EUR 38.43 at Lang & Schwarz on October 13, 2026, 1.40 percent above the Xetra close of EUR 37.90 on October 12, 2026.
The company will report third-quarter 2026 results on November 3, 2026.

3D-Architekturrender eines modernen Glas- und Stahlgebäudes mit begrüntem Vorplatz — Architektur-Render zeigt modernes Glasgebäude als Sinnbild für Fresenius Medical Care AG DE0005785802 mit minimalistischer Fassade, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) named Shervin J. Korangy as chief executive officer and chair of the Management Board effective October 12, 2026. The appointment was announced on October 7, 2026, when the Supervisory Board unanimously chose the 51-year-old executive to succeed Helen Giza, according to Fresenius Medical Care. FMC stock was trading at EUR 38.43 at Lang & Schwarz on October 13, 2026 at 9:34 a.m. CEST, 1.40 percent above the Xetra close of October 12, 2026 at EUR 37.90.

Leadership change meets an execution test

Korangy takes over after a transformation program that management said had improved efficiency and profitability. His mandate covers long-term profitable growth, innovation and wider access to renal care, while the company operates 3,513 dialysis clinics serving approximately 290,000 patients, according to the October 7 release.

The timing places the leadership handover close to the next quarterly report. Fresenius Medical Care's investor calendar lists third-quarter 2026 results for November 3, 2026, creating a defined checkpoint for the new management team.

Second-quarter figures show the trade-off

Fresenius Medical Care generated EUR 4.86 billion of revenue in the second quarter of 2026, up 1.40 percent from the second quarter of 2025, while net income fell 3.20 percent to EUR 218.00 million. The figures were reported by Europe Says on October 5, 2026.

Operating income without special items rose 20.00 percent to EUR 569.00 million in the quarter, lifting the corresponding margin to 11.70 percent from 9.90 percent. That contrast matters: cost and productivity gains are supporting profitability faster than revenue growth.

What comes before the results?

The investor calendar shows a reporting period from October 20, 2026 through November 2, 2026, followed by the third-quarter results release on November 3, 2026. The dates give investors a clear sequence for assessing Korangy's early priorities and the durability of the transformation benefits.

Analyst pressure remains visible in the market narrative. Truist lowered its price target to USD 24.00 from USD 25.00 on October 12, 2026 and kept a Hold rating, citing midterm healthcare policy uncertainty, according to Markets Insider. The dollar target is separate from the euro reference price and does not establish a direct valuation comparison.

FMC stock holds above the Xetra close

At Lang & Schwarz, FMC stock was trading at EUR 38.43 on October 13, 2026 at 9:34 a.m. CEST, up EUR 0.53 or 1.40 percent versus the Xetra close of October 12, 2026 at EUR 37.90. The further course of trading is shown by the continuously updated real-time quote of FMC stock.